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ABSTRACT  Because  platelet-derived  growth  factor  (PDGF)  may  be  released  at  sites where 
neutrophil  proteinases  may also  be released,  we examined the effects  of neutrophil elastase 
and cathepsin G upon the chemotactic  and  mitogenic activities  of PDGF.  Elastase abolished 
the chemotactic activity of PDGF for fibroblasts  but had no effect on its chemotactic activity 
for monocytes,  or on  its mitogenic activity  for 3T3 cells  or its capacity to  bind to 3T3 cells. 
Cathepsin G had no effect upon the chemotactic or mitogenic activities of PDGF. In contrast, 
trypsin  eliminated  the chemotactic  activity  of PDGF  for monocytes  and  fibroblasts  and  the 
mitogenic  activity  of PDGF.  After reduction  and alkylation,  PDGF  retained  full  chemotactic 
activity  for fibroblasts  and  monocytes  but  exhibited  no  mitogenic  activity  and  only  limited 
binding to 3T3 cells.  These  results  indicate separate  domains on PDGF for fibroblast chemo- 
tactic and  mitogenic  activity  and for monocyte and fibroblast  chemotactic  activity and  raise 
the possibility that the biological activities  of PDGF may be modified  selectively  in vivo. The 
findings further suggest that the majority of PDGF receptors on fibroblasts mediate mitogenic 
activity  and  that  only  a  minority  of the  PDGF  receptors  on  fibroblasts  are  responsible  for 
chemotactic activity. 
Human platelet-derived growth factor (PDGF) ~  is a glycopro- 
tein of -30,000 mol wt that contains two polypeptide chains 
joined  through  disulfide  linkages  (1,  9,  16). Stored  in  the 
alpha-granules of platelets and  released  when  platelets  are 
activated by blood clotting and contact with sites of injury 
(6),  PDGF  is  a  potent  chemotactic factor for  neutrophils, 
monocytes, fibroblasts, and smooth muscle cells (11,  13,  14, 
30,  33) and a strong mitogen for fibroblasts, smooth muscle 
cells,  and  glial  cells  (27,  35).  Thus,  PDGF  may  play  an 
important role in  the  migration of inflammatory cells and 
connective tissue cells to sites of inflammation and injury and 
in the repair and restructuring of injured tissues. 
Similar to many other chemotactic factors, PDGF causes 
neutrophils  to  release superoxide anion  and  lysosomal en- 
J  Abbreviations  used in this paper:  FCL,  fetal calf ligament fibro- 
blasts;  HLE,  human  neutrophil  elastase; PDGF,  platelet-derived 
growth factor. 
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zymes and  to  undergo  adhesion  and  aggregation  (36,  38). 
Accordingly, besides recruiting neutrophils, PDGF may also 
cause neutrophil activation generally. Since neutrophils con- 
tain two proteinases with different specificity, human neutro- 
phil elastase (HLE) and cathepsin G, that are released at sites 
of inflammation (28)  and  during coagulation  (26,  37)  and 
thus  may interact with  PDGF and  other  platelet products 
(23), we thought it would be of interest to examine the effects 
of these proteinases on the chemotactic and mitogenic activ- 
ities of PDGF. We observed that HLE abolishes the chemo- 
tactic activity of PDGF for flbroblasts without changing either 
the chemotactic activity of PDGF for monocytes or its mito- 
genic activity. In contrast, cathepsin G has no effects on either 
the chemotactic or mitogenic activities of PDGF. These find- 
ings were extended using PDGF that was modified by reduc- 
tion and alkylation. This chemical modification changed the 
biological activity of PDGF so that the mitogenic activity was 
351 abolished  without  changing chemotactic activity for either 
fibroblasts or monocytes. 
These results indicate complex relationships between the 
structure and function of PDGF.  It appears that the active 
site of PDGF  for chemotaxis is  different  for different cell 
types and that different sites on PDGF are involved in  its 
chemotactic activity and mitogenic activity for flbroblasts. 
MATERIALS  AND  METHODS 
Materials:  Swiss mouse 3T3  fibroblasts (CLL92) were obtained from 
the American Type Culture Collection (Rockville, MD).  Fetal calf ligament 
fibroblasts (FLC) were obtained from explants of fetal calfligamentum nuchae, 
using the procedure  of Mecham  el al. (25).  Fetal calf serum was from  KC 
Biological (Lenexa,  KS);  other tissue culture reagents were provided by the 
Basic Cancer Center, Washington University Medical Center, St. Louis, MO. 
Monocytes and  neutrophils were prepared from  peripheral venous blood of 
healthy  volunteers (31).  Cell  culture  cluster plates (24  wells,  16-mm  well 
diameter) were obtained from Costar, Data Packaging (Cambridge, MA). 
PDGF I and II were purified from human platelet-rich plasma as described 
previously (9). PDGF II, which has similar  chemotactic and mitogenic activities 
to PDGF I 09, 30),  was used in all experiments except in the experiments of 
reductive alkylation where a mixture of PDGF I and PDGF I| was used. PDGF 
I1 was labeled with '251 as previously described (18). Approximately, 0.7 mol of 
iodide was incorporated per mole of PDGF, yielding a specific radioactivity of 
16 #Ci/t~g ~2sI-PDGF. 
NaJ2~l (17 Ci/mg) and  [3H]methyl thymidine (79.4  Ci/mmol) were pur- 
chased from  New  England  Nuclear (Boston,  MA).  HLE  and  cathepsin G, 
purified from  neutrophils in  human  sputum,  were  kindly provided by  Dr. 
Edward J. Campbell (The Jewish Hospital of St. Louis at Washington University 
Medical Center).  The  catalytic activities of these enzymes were determined 
using  fibronectin  and  synthetic peptides  as  substrates  (4,  5,  29).  Porcine 
pancreatic  trypsin, dithiothreitol, and  iodoacetamide were  purchased  from 
Sigma Chemical Co. (St. Louis, MO). 
Proteolysis of PDGF:  5  ~g  of  PDGF  was  dispensed  into  1.5-ml 
polypropylene microfuge tubes,  to  which  was added  50  ng of either HLE, 
cathepsin G, or trypsin to a final reaction volume of 100 ~1 in PBS, pH 8.0. 
Enzyme or PDGF alone served as controls. For reaction mixtures containing 
HLE or cathepsin G, the reactions were held at 37"C for up to 24 h; aliquots 
were removed at 0,  1, 2, 6, and 24 h and then rapidly frozen. For the reaction 
mixtures containing trypsin, incubation was held for a  maximum of 2  h  at 
which time the enzyme was inhibited by the addition of 250 ~g of aprotinin 
(Trasylol, Bayer AG, Wuppertal, Federal Republic of Germany). All reaction 
mixtures were stored at -70"C until use. 
Reduction and Alkylation of PDGF:  5 #g of PDGF in 4 ~1 of 0.5 
M ammonium bicarbonate was mixed with 28 ~tl of 20 mM dithiothreitol also 
in 0.5 M ammonium bicarbonate. The reaction vessel was gased with nitrogen 
and kept in the dark at room temperature for 2  h.  The reduced PDGF was 
alkylated for 30 min by addition of 8 #1 of 160 mM idodacetamide in 0.5 M 
ammonium bicarbonate. Reduced and alkylated PDGF was stored at -70"C 
until use. 
Chemotaxis  Assay:  Chemotaxis was  assayed  in  modified  Boyden 
chambers using either monocytes or FCL,  according to  methods previously 
reported (31, 32). Briefly, target cells in the upper compartment (human venous 
blood mononuclear cells, 2.5 x  106 cells/ml or FCL,  1.2 x  l0  s cells/ml) were 
separated from PDGF in the lower compartment by two micropore membranes, 
either a 5-um micropore for mononuclear cells or an 8-#m micropore for FCL 
overlaying a 0.45-urn micropore membrane. At the completion of the incuba- 
tion period, 2  h  for mononuclear cells and 6  h  for FCL, the chambers were 
disassembled, the  membranes  stained,  and  the  cells migrating through  the 
upper membrane counted at high dry magnification (x 400). The results were 
expressed as net cells migrating per grid for monocytes or cells per field for 
fibroblasts by correcting for migration in the absence of PDGF in the lower 
compartment. All experiments were done in triplicate and included positive 
controls of fresh PDGF, 30 ng/ml. 
Mitogenic Activity Assay:  The  mitogenic activity of PDGF  was 
determined by PDGF-dependent incorporation of [3H]thymidine into 3T3 or 
FCL cell DNA, as described elsewhere (19). 
Binding Assay:  Binding of t251-PDGF  to  3T3  cells or FCL was per- 
formed as described previously (18). Briefly, 50 ng of ~2~I-PDGF together with 
either native PDGF, reduced and alkylated PDGF, or PDGF treated with HLE 
for 24 h at 37"C was incubated in  1 ml of the binding medium with 3T3 cells 
or  FCL  that  had  been grown  to  confluence in  24-well Costar dishes. Since 
previous studies had shown equilibrium at  I h  at room temperature (18),  we 
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performed  assays at  room  temperature  and  terminated  them  after  1  h  by 
washing the cells three times with PBS.  The cells were solubilized with 0.4 ml 
of 0.4 M  NaOH; 0.2 ml was taken for measurement of radioactivity. Specific 
binding was defined as the total radioactivity minus the radioactivity in the 
presence of 100-fold excess of unlabeled PDGF (5 ~g/ml). 
Protein  Concentration:  Protein concentration was determined by 
Bio-Rad protein microassay (Bio-Rad Laboratories, Richmond, CA) or by the 
method of Lowry et al. (24). 
SDS PAGE:  15% SDS PAGE was carried out according to the procedure 
of Laemmli (22). Gels were stained with Coomassie Brilliant Blue and destained 
with 10% 2-propanol/10% acetic acid. In the absence of a reducing agent, the 
molecular weight of PDGF II was estimated as 28,000.  After reduction, two 
major polypeptide chains (A and B) were observed with apparent molecular 
weights of 16,000 and 14,000, respectively. 
RESULTS 
Effects of Proteolytic Modification on the 
Chemotactic and Mitogenic Activities of PDGF 
HLE gradually destroyed the fibroblast chemotactic activity 
of PDGF  over a  24-h  incubation  (Fig.  1),  but  it  had  no 
influence on the chemotactic activity for monocytes (Fig. 2). 
The effect of HLE in these assays was not due to change in 
the fibroblast PDGF receptor since control mixtures of PDGF 
and HLE without preincubation displayed the full chemotac- 
tic activity of PDGF. Cathepsin G showed no effect upon the 
fibroblast or monocyte chemotactic activities of PDGF even 
after 24 h of incubation whereas trypsin completely abolished 
the chemotactic activity for both fibroblasts and monocytes 
within 2 h (data not shown). 
The mitogenic activity of PDGF for Swiss  3T3  cells and 
FCE after a  24-hour exposure to HLE was identical to the 
mitogenic activity of unexposed PDGF (Figs.  3 and 4). No- 
tably, FCL showed only one-tenth  as much  [3H]thymidine 
incorporation in response to PDGF as did 3T3 cells although 
the binding characteristics of PDGF for both cells types were 
essentially the same (Fig. 5). Cathepsin G had no effect upon 
the mitogenic activity of PDGF, but trypsin completely abol- 
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FIGURE  1  The effect of HLE on the chemotactic activity of PDGF 
for fetal calf ligament fibroblasts. PDGF was incubated at 37°C for 
the periods as indicated and then placed in the lower compartment 
of  modified  Boyden  chambers  with  the  test  cells  placed  in  the 
upper compartment. Chemotaxis is expressed as the net  number 
of cells  migrating (total cells corrected  for  background  migration) 
per  high  power field  (H.P.F.) with  standard  errors  of  the  mean. 
Incubation for 6  h and overnight with  HLE produced a significant 
reduction in chemotactic activity. HLE alone is not chemotactic for 
fibroblasts and  mixtures of PDGF and  HLE without preincubation 
exhibited the same chemotactic activity as  PDGF  alone (data not 
shown). 04 
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FIGURE  2  The effect of HLE on the chemotactic activity of PDGF 
for  human  monocytes. The  experimental procedure was as  de- 
scribed for Fig. 1 except that the incubation period of the assay 
was 2 h and the results are expressed as cells per high power grid 
(M.P.G.). HLE  alone is  not chemotactic for  monocytes (data  not 
shown). 
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FIGURE  3  The effect of HLE upon the mitogenic activity of PDGF 
for 3T3  cells.  3T3  cells  were  incubated for 20  h  in  Dulbecco's 
modified Eagle's medium containing [3H]thymidine, 0.2 #Ci/v.g per 
ml, and  PDGF that either had  not been exposed to HLE or had 
been exposed to HLE for 6 h or overnight. The results represent 
incorporation of the radiolabel into trichloroacetic acid precipitable 
material. HLE alone has no mitogenic activity (data not shown). 
ished the mitogenic activity of PDGF for both 3T3 cells and 
FCL. On SDS PAGE, HLE did not influence the mobility of 
PDGF nor did it significantly change the  migration of the 
polypeptide chains (the A and B chains) after reduction (data 
not  shown),  which  suggests that  the  cleavage produced  by 
HLE is located at or near the N- and C-terminal ends of either 
the A or B chains. 
Effects of Reduction and AIkylation on the 
Chemotactic and Mitogenic Activities  of PDGF 
While the present investigations were in progress, Williams 
and his co-workers (38) reported that reductive alkylation of 
PDGF with dithiothreitol and iodoacetamide resulted in loss 
of mitogenic  activity  for  fibroblasts  without  affecting  the 
chemotactic activity for monocytes. Accordingly, they sug- 
gested that the active sites for the chemotactic activity and 
mitogenic activity of PDGF are at different loci on the mol- 
ecule. However, since different cells types were compared for 
mitogenic and chemotactic activities, the study did not prove 
that the active sites on PDGF for mitogenic and chemotactic 
activity for fibroblasts are different. 
Reductive  alkylation  had  no  effect  on  the  chemotactic 
activity of PDGF for either FCL (Fig.  6,  left) or monocytes 
(Fig. 6, right) but abolished the mitogenic activity of PDGF 
(Table I). Thus, these results support the findings reported by 
Williams et al.  (38)  and indicate that their results were not 
due to comparing different cell types. The present observa- 
tions with HLE suggest further that the chemotactically active 
sites on PDGF are different for fibroblasts and monocytes in 
that HLE abolished chemotactic activity for fibroblasts with- 
out changing the chemotactic activity for monocytes. 
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FIGURE 4  The effect of HLE on the mitogenic activity of PDGF for 
fetal calf ligament fibroblasts. The  experimental procedure is as 
described  in Fig. 3. 
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FIGURE  5  Binding of 1251-PDGF to 3T3 cells and fetal calf ligament 
fibroblasts. Cells were incubated with radiolabeled PDGF for 1 h at 
22°C,  washed,  and  lysed  with  0.4  M  NaOH  for  15  min.  The 
radioactivity of the lysates was measured and corrected for nonspe- 
cific binding. See Materials and Methods for further details. 
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FIGURE 6 The effect of reduction (dithiothreitol) and alkylation
(iodoacetamide) upon the chemotactic activity of PDGF . (Top) Fetal
calf ligament fibroblasts. (Bottom) Monocytes. PDGF waschemically
modified as described in Materials and Methods andtheresults are
presented as described in Fig. 1 .
TABLE I
Effect of Reduction andAlkylation on the Mitogenic Activity of
* 5 jAg of PDGF was reduced and alkylated with 0.6 Amol of dithiothreitol
(DTT) and 1 .2 pmol of iodoacetamide as described in Materials and Meth-
ods.
= PDGF preparations were assayed at a concentration of 5 ng/ml; standard
error of triplicate measurements.
Binding of Modified PDGF to Fibroblasts
Although HLE abolished the fibroblastchemotactic activity
of PDGF, HLE did not change the mitogenic activity of
PDGF. Accordingly, it seemed probable that HLE does not
change the binding of PDGF to fibroblasts. Indeed, unlabeled
PDGF competed with "'I-PDGF for 3T3 cells binding as
effectively for HLE exposure as before (Fig. 7).
Since reductive alkylation completely abolished the mito-
genic activity of PDGF, reduced and alkylated PDGF should
be an ideal ligand to test whether most ofthe PDGF receptors
on fibroblasts are responsible for mitogenic activity. As shown
in Fig. 7, reductive alkylation markedly diminished PDGF
binding to fibroblasts as reflected by less effective competition
of reduced and alkylated PDGF against `ZSI-PDGF for fibro-
blastbinding. The partial competition seen with reduced and
alkylated PDGF is not due to residual unmodified PDGF
because after reductive alkylation no intact PDGF was de-
tected on analysis with 15% SDS PAGE. It is likely that the
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limited inhibition of "'I-PDGF binding by reduced and al-
kylated PDGF is through the same mechanism of inhibition
seen with a number of basic proteins or polypeptides (18).
DISCUSSION
The presence of both chemotactic and mitogenic activities in
PDGF raises the interesting and important question of
whether these activities derive from the same site on the
PDGF molecule. It is plausible that these two properties of
PDGF might involve different sites since it is known that
substances may be mitogenic without being chemotactic and
vice versa. For example, epidermal growth factor, a mitogen
for fibroblasts, does not have fibroblast chemotactic activity
(33), whereas platelet factor 4 and 0-thromoglobulin are
chemotactic but not mitogenic for fibroblasts and PDGF is
chemotactic but not mitogenic for inflammatory cells (un-
published results).
The present findings with HLE exposure and with reductive
alkylation, together with work of others with reduced and
alkylated PDGF (38, 39), indicate clearly that the chemotactic
activity and mitogenic activity of PDGF are separable. Table
II summarizes the sensitivities ofthe chemotactic activity and
mitogenic activities of PDGF to proteolytic enzymes and
reductive alkylation . As shown, the fibroblast chemotactic
activity of PDGF is sensitive to HLE and trypsin but not to
cathepsin G, whereas only trypsin abolished the chemotactic
activity of PDGF for monocytes. The mitogenic activity of
PDGF is resistant to HLE and cathepsin G, but not to trypsin.
FIGURE 7
￿
The binding of "'I-PDGF to 3T3 cells in the presence of
PDGF that had been exposed to HLE for 24 h or had been reduced
and alkylated. Confluent 3T3 cells were incubated with various
concentrations of modified PDGF and 50 ng/ml of tzsl-PDGF. After
1 h at room temperature the cells were washed and assayed for
cell-associated 1251-PDGF. The specific binding of "'I-PDGF to 3T3
cells (12,000 cpm/well) was taken as 100%.
TABLE II
Effects of Proteolytic Enzymes and Reduction and Alkylation on
the Chemotactic andMitogenic Activities of PDGF
Chemotactic
- denotes no effect on the activity; + indicates the activity is markedly
reduced or abolished (<5% of control) .
PDGF*
Assay medium Mitogenic activity=
dpm/well
0
0 z
0 m
Control 4,432 ± 1,710 0
PDGF 17,306 ± 1,388 a
PDGF + iodoacetamide 16,268 ± 342
H
N
PDGF + DTT + iodoacetamide 5,038 ± 368
Mono-
cyte
activity*
Fibro-
blast
Mito-
genic
activity*
HLE - + -
Cathepsin G - - -
Trypsin + + +
Reduction and alkylation - - +In  contrast,  reductive  alkylation  has  no  influence  on  the 
chemotactic activity of PDGF for either fibroblasts or mon- 
ocytes but eliminates its mitogenic activity. Thus, the active 
sites for mitogenic activity and  chemotactic activity in  the 
PDGF  molecule are different and the  receptors for PDGF 
chemotactic activity in fibroblasts and monocytes also appear 
to be different. 
Studies of PDGF receptors on fibroblasts including  NIH 
3T3 cells (17), Swiss mouse 3T3 cells (18), normal rat kidney 
cells  (17),  and human fibroblasts (15)  have demonstrated a 
single  class of receptors with a  Kd of 1 nM  and 2-4  x  l05 
receptors per cell. The present study, however, has provided 
evidence for two functionally distinct receptors in fibroblasts, 
one  for  chemotactic  activity  and  the  other  for  mitogenic 
activity. There are several possible explanations for the ap- 
parent discrepancy between the single class of PDGF receptors 
on  fibroblasts and the  separate PDGF functions:  First,  the 
mitogenic and chemotactic responses of fibroblasts to PDGF 
may require  different  percentages  of occupancy  of PDGF 
receptors. Thus, mitogenic responses of fibroblasts to PDGF 
might  involve  a  high  percentage  of occupancy  of PDGF 
receptors whereas expression of chemotaxis may involve only 
a low percentage. That HLE abolishes fibroblast chemotactic 
activity but has no effect on either mitogenic activity of PDGF 
or PDGF binding to fibroblasts appears to exclude this pos- 
sibility. Second, there may be another class of  PDGF receptors 
involved in mediating the fibroblast chemotactic activity, but 
these receptors are few and therefore difficult to detect. This 
concept is supported by recent studies of inflammatory cells 
that demonstrate only about 2,000 to 6,000 PDGF receptors 
per cell  (21).  However, even by increasing the sensitivity of 
binding analysis by using a ligand with 10-fold higher specific 
radioactivity (160 uCi/ug), we could not detect a second, high- 
affinity receptor. A third possibility, which seems most attrac- 
tive  at  this  point,  is  that  there  are  two  groups  of PDGF 
receptors, one for chemotactic activity and one for mitogenic 
activity, which have similar Kd's and thus can not be distin- 
guished by direct binding analysis. 
This hypothesis would suggest that the majority of PDGF 
receptors on fibroblasts mediate mitogenic activity and that 
only a  minority of the PDGF receptors are responsible for 
chemotactic activity, since HLE-treated PDGF competes with 
native PDGF for binding to fibroblasts and is mitogenic even 
though it lacks chemotactic activity for flbroblasts. 
The sensitivity of PDGF fibroblast chemotactic activity to 
HLE but not to cathepsin G is of interest, suggesting that the 
active site for chemotactic activity is located in a  small re- 
gion(s) of the PDGF molecule. HLE preferentially cleaves at 
Val-X bonds and to a lesser extent at Ala-X bonds (2) whereas 
cathepsin G  cleaves peptide bonds adjacent to the carboxyl 
group  of phenylalanine,  leucine,  tyrosine,  isoleucine,  and 
methionine residues (3, 40). The inactivation of PDGF chem- 
otactic activity by HLE but not by cathepsin G  is similar to 
the capacity of HLE but not cathepsin G to cleave IgG (34). 
In their study showing that after reductive alkylation PDGF 
has no mitogenic activity for flbroblasts but retains chemo- 
tactic activity for monocytes, Williams et al.  (38)  observed 
that reduced PDGF was less effective than native PDGF in 
causing lysosomal enzyme release from cytochalasin-treated 
inflammatory cells. This finding indicated that reduced PDGF 
only partially activates inflammatory cells even though it is 
fully  active  as  a  chemoattractant.  Whether  proteolysis  of 
PDGF by HLE impairs the effectiveness of PDGF to cause 
lysosomal  degranulation  from  inflammatory  cells,  even 
though it does not alter the chemotactic activity of PDGF for 
monocytes, remains to be determined. 
PDGF contains two homologous but not identical polypep- 
tide chains, A and B, which are linked by disulfide linkages. 
The amino acid sequence of the A chain is 60% homologous 
to that of the B chain (7,  20).  This novel, two polypeptide 
structure raises the question  of whether the active sites for 
mitogenic activity and  chemotactic activity are  located  on 
different chains. Since p28 vsis, the transforming protein of the 
simian sarcoma virus, which is 92%  homologous to the  A 
chain of PDGF, has identical specific mitogenic activity (units 
per nanomole) with PDGF (8),  it is likely that the A chain 
carries the active site for the mitogenic activity of PDGF. At 
this time there is no evidence to suggest which chain(s) carries 
the chemotactic activity of PDGF. The B chain may contain 
the active site for chemotactic activity or the A chain  may 
have the active sites for both the mitogenic activity and the 
chemotactic activity. 
The C-terminal part of the A chain is rich in basic amino 
acid  residues which  are preferred cleavage sites for trypsin 
compared  with  the  N-terminal  part  of that  chain  (7).  In 
addition, protamine has been shown to be a strong inhibitor 
for '25I-PDGF binding to monocytes, neutrophils, and fibro- 
blasts and a potent inhibitor of chemotactic activity of PDGF 
for these cells (1 I, 18, 21).  These results are compatible with 
the  potential  role  of basic  amino  acid  residues  at  the  C- 
terminal  part  of either  the  A  chain  or the  B  chain  in  the 
binding  of PDGF  to  receptors  for  mitogenic  activity  and 
chemotactic activity. 
While the present study emphasizes modifications of PDGF 
that may produce alterations in its activity as a chemoattrac- 
tant, Grotendorst (12) has shown that target cells for PDGF 
chemotactic activity can also be modified in their responsive- 
ness to PDGF. Thus, 3T3 cells showed differences in chem- 
otaxis to PDGF depending  upon  their rate of proliferation 
and whether they had been transformed with phorbol myris- 
tate acetate. These changes appeared to be specific for PDGF 
since they were associated with decreased PDGF binding and 
did not extent to chemotaxis to fibronectin. 
The capacity of HLE  to  dissociate the  chemotactic and 
mitogenic activities of PDGF may be important in vivo since 
neutrophils may be attracted by PDGF to sites of inflamma- 
tion and HLE is a  secretory product of neutrophils.  In any 
event, the present study suggests that the biological effects of 
PDGF can be modulated selectively by factors that are re- 
leased at the same sites as PDGF. 
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